Future studies should use a longitudinal design to investigate the causal role of immune pathways in development of negative symptoms in patients with established schizophrenia and test the benefit of using immune biomarkers such as IL-8, IL-6, IL-10 and TNF-α to guide anti-inflammatory treatment for severe and refractory negative symptoms. This evidence concerns the gene IL6 and schizophrenia.